Specialty Pharmacy

Timolol eyedrops may have a potential role in managing acute migraine for some patients.

In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment.

A 2-part trial shows a new antibody that suppresses HIV when combined with antiretroviral therapy (ART).

Despite universal access to care afforded to US military service members, there is a need to improve and expand access to PrEP for those patients at highest risk for HIV infection.

Top news of the day from across the health care landscape

Officials with the FDA have approved bevacizumab (Avastin, Genentech) in combination with carboplatin and paclitaxel for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pembrolizumab (Keytruda, Merck) gained FDA approval for 2 new oncology indications.

On National HIV Testing Day, which takes place on June 27, Walgreens and Greater Than AIDS will team up with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis.

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

The Working Group examined the insulin supply chain and the factors that impact the costs of and access to insulin products.

Cemiplimab induced a response in approximately half of patients with advanced cutaneous squamous-cell carcinoma.

Researchers studied the effects of an antioxidant-enriched multivitamin on inflammation and health outcomes in patients with cystic fibrosis.

Top news of the day from across the health care landscape

Allergan announced positive topline results from CGP-MD-01, a phase 2b/3 clinical trial of atogepant.

Specialty drugs with limited distribution networks require pharmacies to put together an extensive request for proposal to gain access.

Top news of the day from across the health care landscape

The researchers found that total duration of opioid use was the strongest predictor of misuse, with each refill and additional week of opioid use associated with an increased rate of misuse.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the importance of collaboration during the pharmacy accreditation process.

Officials with the FDA have granted GBC0905, for the treatment of facioscapulohumeral muscular dystrophy (FSHD), an Orphan Drug Designation.

Patients with both private and public insurers face high denial rates across the United States for life-saving hepatitis C drugs, despite changes in restrictions and increased price competition.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape

A look at last week's top stories in the world of pharmacy.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses data collection and analytics services that aggregators can offer manufacturers.

With the approval, rituximab has become the first biologic therapy approved by the FDA for PV, and the first major advancement in treatment of the condition in 6 decades.

Delayed or failed degree completion is associated with much higher economic consequences for advanced-degree as compared to baccalaureate-degree programs.

Indazole chloride may be able to reduce disability burden in patients with multiple sclerosis by producing good inflammation that promotes axon myelination.